Mice transplanted with responder fecal microbiome showed an improved response to anti-PD-L1 therapy, reduced tumor size, and higher levels of CD8-positive T cells compared to the recipient mice with non-responder fecal microbiome (Gopalakrishnan et al., 2018). This evidence concerns the gene CD8A and neoplasm.